- Expanded collaboration between SOPHiA GENETICS (SOPH, Financial) and AstraZeneca to advance global liquid biopsy testing.
- Deployment of MSK-ACCESS powered by SOPHiA DDM to reach 30 clinical institutions by 2025.
- Real-world data confirms consistent analytical performance across diverse laboratory settings.
SOPHiA GENETICS (SOPH), a leader in data-driven medicine, has announced an expansion of its collaboration with AstraZeneca, aiming to accelerate the deployment of its liquid biopsy testing globally. This strategic initiative plans to extend the reach of MSK-ACCESS, powered by SOPHiA DDM, across 30 clinical institutions worldwide by 2025. This move signifies a significant scaling of their deployment infrastructure and aims to advance the adoption of this innovative diagnostic approach.
The MSK-ACCESS liquid biopsy test utilizes advanced algorithms to detect genomic alterations from a single blood draw by analyzing circulating tumor DNA (ctDNA). This cutting-edge technology offers a less invasive and cost-effective alternative when traditional tissue biopsies are impractical due to cost, time, or procedural invasiveness.
Significantly, new data presented at the American Association for Cancer Research (AACR) reveals that MSK-ACCESS, with SOPHiA DDM, demonstrates consistent accuracy and high analytical performance across different laboratory settings. This finding addresses a major challenge in liquid biopsy adoption, known as site-to-site result discordance, and confirms that the technology aligns with the high standards previously set by Memorial Sloan Kettering Cancer Center.
This expanded collaboration is also expected to contribute to AstraZeneca's global real-world evidence initiatives, further validating the clinical impact of decentralized liquid biopsy testing in diverse healthcare systems. Both companies aim to explore how liquid biopsies can complement traditional solid tissue tests, thus enhancing patient care and treatment selection.
Ross Muken, President of SOPHiA GENETICS, expressed optimism about the expanded deployment, stating it marks a significant step in scaling next-generation oncology diagnostics globally. Investors and stakeholders can learn more about this initiative at the AACR annual meeting in Chicago or by visiting SOPHiAGENETICS.COM.
